American BioMed
This article was originally published in The Gray Sheet
Executive Summary
Stockholder and underwriter of previous American BioMed offering Robert Todd Financial Corp. files statement with the Securities and Exchange Commission in connection with the sale of 100,000 shares of the catheter manufacturer's stock. The company will not receive any proceeds from the sale of the stock, which may be offered "from time to time" by the seller. The prospectus notes that the firm is currently conducting limited human trials of its 8 French OmniCath atherectomy catheter for peripheral use and is developing 3.8 and 4.5 French versions of the device for use in coronary arteries. The firm is also developing several versions of its Evert-O- Cath toposcopic catheter for coronary and non-coronary therapeutic uses. A preliminary version of the Evert-O-Cath has been approved for non-coronary diagnostic applications; the company currently is awaiting 510(k) clearance for modifications that were made to the device. The firm also is in preliminary stages of development of cardiac assist devices....
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.